$95.68
1.25% yesterday
NYSE, Oct 22, 10:00 pm CET

PerkinElmer Stock price

$95.68
+9.41 10.91% 1M
+3.35 3.63% 6M
-15.93 14.27% YTD
-23.10 19.45% 1Y
-37.04 27.91% 3Y
-29.52 23.58% 5Y
+46.69 95.31% 10Y
+74.47 351.11% 20Y
NYSE, Closing price Wed, Oct 22 2025
-1.21 1.25%

Key metrics

Basic
Market capitalization
$11.1b
Enterprise Value
$13.3b
Net debt
$2.2b
Cash
$991.9m
Shares outstanding
116.3m
Valuation (TTM | estimate)
P/E
39.5 | 19.3
P/S
4.0 | 3.8
EV/Sales
4.8 | 4.6
EV/FCF
26.5
P/B
1.5
Dividends
DPS
$0.28
Yield 1Y | 5Y
0.3% | 0.2%
Growth 1Y | 5Y
0.0% | 0.0%
Payout 1Y | 3Y
12.7% | 6.9%
Increased
0 Years
Financials (TTM | estimate)
Revenue
$2.8b | $2.9b
EBITDA
$812.7m | $867.5m
EBIT
$399.8m | $790.3m
Net Income
$285.2m | $576.9m
Free Cash Flow
$503.0m
Growth (TTM | estimate)
Revenue
3.3% | 5.6%
EBITDA
1.9% | 2.2%
EBIT
8.4% | 87.7%
Net Income
68.3% | 113.4%
Free Cash Flow
31.3%
Margin (TTM | estimate)
Gross
55.9%
EBITDA
29.0% | 29.8%
EBIT
14.3%
Net
10.2% | 19.8%
Free Cash Flow
18.0%
Financial Health
Equity Ratio
61.9%
Return on Equity
3.5%
ROCE
3.4%
ROIC
-
Debt/Equity
0.4
More
EPS
$2.4
FCF per Share
$4.3
Short interest
9.1%
Employees
11k
Rev per Employee
$250.0k
Show more

Is PerkinElmer a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,012 stocks worldwide.

PerkinElmer Stock Analysis

Unlock Scores for Free

Analyst Opinions

26 Analysts have issued a PerkinElmer forecast:

17x Buy
65%
8x Hold
31%
1x Sell
4%

Analyst Opinions

26 Analysts have issued a PerkinElmer forecast:

Buy
65%
Hold
31%
Sell
4%

Financial data from PerkinElmer

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
2,798 2,798
3% 3%
100%
- Direct Costs 1,233 1,233
2% 2%
44%
1,565 1,565
5% 5%
56%
- Selling and Administrative Expenses 965 965
5% 5%
34%
- Research and Development Expense 205 205
2% 2%
7%
813 813
2% 2%
29%
- Depreciation and Amortization 413 413
4% 4%
15%
EBIT (Operating Income) EBIT 400 400
8% 8%
14%
Net Profit 285 285
68% 68%
10%

In millions USD.

Don't miss a Thing! We will send you all news about PerkinElmer directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

PerkinElmer Stock News

Neutral
Business Wire
9 days ago
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY) today released its annual Impact Report, a comprehensive reflection of the Company's sustainability, social and governance strategy, initiatives and performance. This year's report, Progress with Purpose: Science and Sustainability, highlights the Company's strengthened partnerships, product innovation, sustainability driven investment...
Neutral
Business Wire
17 days ago
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced that it will release its third quarter 2025 financial results prior to market open on Monday, October 27, 2025. The Company will host a conference call the same day at 8:00 a.m. ET to discuss these results. Prahlad Singh, president and chief executive officer, and Max Krakowiak, chief financial officer, will host the c...
Neutral
Business Wire
21 days ago
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY) today announced a program for expansion of its type 1 diabetes (T1D) offering to include a population-scale assay for early detection with support from Sanofi (EURONEXT: SAN and NASDAQ: SNY). Revvity will develop a T1D 4-plex in vitro diagnostic (IVD) assay based on its existing research-use (RUO) 3-plex assay. T1D is a lifelong, progr...
More PerkinElmer News

Company Profile

PerkinElmer, Inc. engages in the provision of products, services, and solutions for diagnostics, food, environmental, life sciences, and applied markets. It operates through the following segments: Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment comprises of technologies that help life sciences researchers better understand diseases and develop treatments. The Diagnostics segment offers instruments, reagents, assay platforms, and software to hospitals, medical labs, clinicians, and medical research professionals to help improve the health of families. The company was founded by Richard Scott Perkin and Charles W. Elmer on April 19, 1937 and is headquartered in Waltham, MA.

Head office United States
CEO Prahlad Singh
Employees 11,000
Founded 1937
Website www.revvity.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today